---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-034711"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-07-27T12:30:31+00:00"
generated_at: "2026-07-27T12:35:26.108350+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# bioAffinity Technologies publishes clinical framework for CyPath Lung in nodule evaluation

## Summary
- White paper by CMO Gordon Downie proposes specialty-specific pathways for pulmonology, primary care, oncology using CyPath Lung.
- CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV in high-risk patients with small nodules.
- Company reports 7.78M shares outstanding, market cap ~$5.1M as of July 24, 2026.
- CyPath Lung analyzes sputum for lung microenvironment, not blood-based, providing real-time information.
- Complete white paper available at https://bit.ly/cypath-lung-whitepaper3.

## SEC filing metadata
- accession: 0001493152-26-034711
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-07-27T12:30:31+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226034711/0001493152-26-034711-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226034711/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-034711
- JSON: https://secwatch.observer/filing/0001493152-26-034711.json
- Plain text: https://secwatch.observer/filing/0001493152-26-034711.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.